Emily Cicali, Pharm.D.

Emily Cicali

Clinical Assistant Professor

Pharmacotherapy and Translational Research


EMAIL: emily.cicali@cop.ufl.edu

PHONE: 352-273-7919

CV: Link to CV


Emily Cicali, Pharm.D., received her Doctor of Pharmacy degree from Philadelphia College of Pharmacy, University of the Sciences in 2015. She then completed a Pharmacy Practice Residency at Tabula Rasa HealthCare in Geriatric Personalized Medicine. After her residency, she was hired to work Tabula Rasa HealthCare at as a Research Pharmacist, as well as adjunct faculty at the Philadelphia College of Pharmacy, focusing on clinical pharmacokinetics and pharmacogenomics implementation. In 2017 she decided to fully transition to academia, which led to her completion of a fellowship in pharmacogenomics at the University of Florida. Cicali is now a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research. Her clinical practice is within the UF Health Personalized Medicine Program and her research interests include clinical implementation of pharmacogenomics as well as further understanding the role of phenoconversion for optimal medication safety.


  • BS in pharmaceutical and Healthcare Studies, Philadelphia College of Pharmacy, University of the Sciences
  • PharmD, Philadelphia College of Pharmacy, University of the Sciences
  • Pharmacy Practice Residency in Geriatric Personalized Medicine and Targeted Therapeutics, Tabula Rasa HealthCare
  • Pharmacogenomics Fellowship, University of Florida, College of Pharmacy


  • 2017–present                     American College of Clinical Pharmacy (ACCP)
  • 2016–present                     International Pharmacetical Federation (FIP)
  • 2016–present                     Pharmacogenomics Research Network (PGRN)
  • 2015–present                     American Society of Clinical Pharmacology and Therapeutics (ASCPT)
  • 2010–present                     American Society of Consultant Pharmacists (ASCP)
  • 2009–present                     American Society of Health-System Pharmacists  (ASHP)


Research Interest

  • Clinical implementation of pharmacogenomics
  • Pharmacokinetic changes caused by CYP-inhibitors (phenoconversion)
  • Survey research to patients and prescribers to determine attitudes and acceptability of pharmacogenomics


  1. Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. Implementation of a Pharmacist-Led Pharmacogenomics Service for PACE (PHARM-GENOME-PACE). J Am Pharm Assoc.2018 Mar 27. piiSE1544-3191(18):30076-1.
  2. Schwartz EJ, Turgeon J,Patel J. et al., Successful Implementation of a Standardized Medication Therapy Management Plus Approach within a Primary Care Setting.J of Amer Board of Family Medicine. 2017 November-December; 30: 701-14.
  3. Bain KT, Schwartz EJ, Chan-Ting R. Reducing Off-Label Antipsychotic Use in Community-Dwelling Older Adults with Dementia: A Narrative Review. J Am Osteopath Assoc. 2017 July; 117:441-50.
  4. Schwartz EJ, Issa AM. The Role of Hospital Pharmacists in the Adoption and Use of Pharmacogenomics and Precision Medicine. Personalized Medicine. Epub 2016 Oct 18.